Tern Plc invests $280,000 in Device Authority convertible loan notes

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (IoT) technology businesses, has announced that it has invested US$280,000 (approximately £209,000) in new unsecured convertible loan notes issued by Device Authority Limited.  The investment in the Device Authority CLNs will be funded from the proceeds of the Company’s recent Open Offer.

The CLNs carry an interest rate of 8 per cent. per annum and the CLNs’ principal amount and accrued interest are convertible on either a change of control of Device Authority, or a fundraising of at least US$5 million (a “Qualifying Fundraise”) undertaken by Device Authority, or, if neither have occurred on 30 June 2027.  On a change of control, the CLNs are convertible at a three times multiple to their face value and the value of accrued interest.  On a Qualifying Fundraise the CLNs are convertible at a 25 per cent discount to the Qualifying Fundraise price.  If neither a change of control nor a Qualifying Fundraise has taken place, the CLNs will mature on 30 June 2027.

As at 30 June 2025, the date of Tern’s last published book valuation, Tern’s holding in Device Authority had a total unaudited book value of £4.0 million. Following the issue of the CLN, Tern’s equity holding in Device Authority will be unchanged and Tern will continue to hold approximately 25.3% of Device Authority’s equity (before any dilution on exercise of share options), although now with a CLN holding of approximately £0.21 million.

As part of the same overall funding round, Device Authority is in the process of raising up to US$1.6 million of funding from existing investors through the issue of CLNs on the same terms.

Jane McCracken, Interim Non-Executive Chair of Tern, said: “We are pleased to be able to provide this further funding to Device Authority, which is part of a larger fundraise by the business to ensure they have sufficient working capital to service significant contracts expected in the near term. We remain very excited by the potential of Device Authority and our other portfolio companies, and are focused on realising value from them as soon as is appropriate.”

Further information on Device Authority

Device Authority is a global leader in Identity and Access Management (IAM) for the IoT; focused on the automotive, medical device (IoMT) and industrial (IIoT) sectors. Device Authority’s KeyScaler™ platform provides zero touch provisioning and complete automated lifecycle management for securing IoT devices and data at scale, with frictionless deployment across device provisioning, authentication, credential management, policy based end-to-end data security/encryption and secure OTA (over the air) and HSM (hardware security module) updates.

Based on Device Authority’s latest statutory accounts for the year ended 31 December 2025, as at that date it had net assets of approximately £11,609,000 and incurred a loss for the year of approximately £1,750,000. Given the historic and statutory nature of these figures, Tern does not consider this to be representative of the current business, trading performance and prospects of Device Authority.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Search